IL92138A - תכשירי רוקחות המכילים פירוקסיקם והכנתם - Google Patents
תכשירי רוקחות המכילים פירוקסיקם והכנתםInfo
- Publication number
- IL92138A IL92138A IL9213889A IL9213889A IL92138A IL 92138 A IL92138 A IL 92138A IL 9213889 A IL9213889 A IL 9213889A IL 9213889 A IL9213889 A IL 9213889A IL 92138 A IL92138 A IL 92138A
- Authority
- IL
- Israel
- Prior art keywords
- mass
- parts
- active ingredient
- particle size
- piroxicam
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title description 31
- 229960002702 piroxicam Drugs 0.000 title description 28
- 239000000203 mixture Substances 0.000 claims description 40
- 239000002775 capsule Substances 0.000 claims description 35
- 239000004480 active ingredient Substances 0.000 claims description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
- 229930195725 Mannitol Natural products 0.000 claims description 16
- 239000000594 mannitol Substances 0.000 claims description 16
- 235000010355 mannitol Nutrition 0.000 claims description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
- 239000008101 lactose Substances 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 229920002261 Corn starch Polymers 0.000 claims description 11
- 239000008120 corn starch Substances 0.000 claims description 11
- 239000000377 silicon dioxide Substances 0.000 claims description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 5
- 238000003825 pressing Methods 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 6
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- FVTSYHPRVGNAQI-UHFFFAOYSA-N 2-aminoethanol;4-hydroxy-2-methyl-1,1-dioxo-n-pyridin-2-yl-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound NCCO.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 FVTSYHPRVGNAQI-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- UDKXQFAVKLBFDG-UHFFFAOYSA-L magnesium;sodium;dodecyl sulfate;octadecanoate Chemical compound [Na+].[Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCC([O-])=O UDKXQFAVKLBFDG-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 229910000906 Bronze Inorganic materials 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000002788 histamine agent Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- -1 piroxicam ethylenediamine salt Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU885621A HU200926B (en) | 1988-10-28 | 1988-10-28 | Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL92138A0 IL92138A0 (en) | 1990-07-12 |
| IL92138A true IL92138A (he) | 1994-08-26 |
Family
ID=10970484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9213889A IL92138A (he) | 1988-10-28 | 1989-10-27 | תכשירי רוקחות המכילים פירוקסיקם והכנתם |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPH02172918A (he) |
| AT (1) | AT399277B (he) |
| CA (1) | CA2001673C (he) |
| DE (1) | DE3936112C2 (he) |
| FR (1) | FR2638357B1 (he) |
| GB (1) | GB2224207B (he) |
| HU (1) | HU200926B (he) |
| IL (1) | IL92138A (he) |
| IT (1) | IT1239542B (he) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| JP2964195B2 (ja) * | 1992-04-28 | 1999-10-18 | エスエス製薬株式会社 | ピロキシカム錠及びその製造法 |
| DE19603402A1 (de) * | 1995-02-24 | 1996-08-29 | Basf Ag | Weichgelatinekapseln |
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| ATE477793T1 (de) * | 1996-06-14 | 2010-09-15 | Kyowa Hakko Kirin Co Ltd | Eine im mund schnell zerfallende tablette |
| EP1070496A4 (en) * | 1998-04-08 | 2004-07-21 | Kyowa Hakko Kogyo Kk | METHOD FOR PRODUCING TABLETS AND TABLET |
| JP2000095674A (ja) | 1998-09-22 | 2000-04-04 | Sato Pharmaceutical Co Ltd | 口腔内崩壊時間短縮化錠剤の製造方法及び装置 |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| BR0317349A (pt) * | 2002-12-16 | 2005-11-16 | Kissei Pharmaceutical | Droga sólida para uso oral |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| US20060105039A1 (en) | 2004-10-21 | 2006-05-18 | Jin-Wang Lai | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| TWI382850B (zh) * | 2005-07-25 | 2013-01-21 | Otsuka Pharma Co Ltd | An oral preparation useful for the determination of pyridine metabolism |
| JP5309262B2 (ja) | 2009-12-02 | 2013-10-09 | アプタリス ファーマ リミテッド | フェキソフェナジン・マイクロカプセル及びそれを含む組成物 |
| KR102105354B1 (ko) | 2012-08-20 | 2020-04-29 | 오츠카 세이야쿠 가부시키가이샤 | 당대사능의 측정 방법 및 그에 사용하는 조성물 |
| CA2906423A1 (en) | 2013-03-15 | 2014-09-18 | Otsuka Pharmaceutical Co., Ltd. | Method of measuring insulin resistance with fatty acid combustion, and composition used herein |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3591584A (en) * | 1968-08-27 | 1971-07-06 | Pfizer | Benzothiazine dioxides |
| GB1308533A (en) * | 1969-06-02 | 1973-02-21 | Pfizer | Benzothiazine dioxides as anti-thombotic agents |
| JPS55129221A (en) * | 1979-03-29 | 1980-10-06 | Kaken Pharmaceut Co Ltd | Preparation of oral preparation containing hardly soluble medicine |
| US4350689A (en) * | 1980-02-15 | 1982-09-21 | American Cyanamid Company | Combinations of agents which give enhanced anti-inflammatory activity |
| US4434164A (en) * | 1981-06-01 | 1984-02-28 | Pfizer Inc. | Crystalline benzothiazine dioxide salts |
| RO88420A (ro) * | 1983-04-25 | 1986-01-30 | Pfizer Inc,Us | Procedeu pentru prepararea unor saruri bazice de piroxican depuse pe suporturi farmaceutice |
| DE3419128A1 (de) * | 1984-05-23 | 1985-11-28 | Bayer Ag, 5090 Leverkusen | Dihydropyridinpraeparate und verfahren zu ihrer herstellung |
| CH663899A5 (fr) * | 1985-03-20 | 1988-01-29 | Nestle Sa | Procede pour la preparation d'une composition a base d'un principe actif de faible hydrosolubilite finement divise. |
| ES8603754A1 (es) * | 1985-07-02 | 1986-01-01 | Ferrer Int | Procedimiento de obtencion de particulas de 4-hidroxi-2-me- til-n-2-piridil-2h-1,2-benzotiazina-3-carboxamida-1,1-dioxi-do(piroxicam) recubiertas |
-
1988
- 1988-10-28 HU HU885621A patent/HU200926B/hu unknown
-
1989
- 1989-10-19 JP JP1270514A patent/JPH02172918A/ja active Pending
- 1989-10-27 IT IT22164A patent/IT1239542B/it active IP Right Grant
- 1989-10-27 GB GB8924286A patent/GB2224207B/en not_active Expired - Lifetime
- 1989-10-27 AT AT0247489A patent/AT399277B/de not_active IP Right Cessation
- 1989-10-27 CA CA002001673A patent/CA2001673C/en not_active Expired - Fee Related
- 1989-10-27 IL IL9213889A patent/IL92138A/he not_active IP Right Cessation
- 1989-10-27 FR FR8914117A patent/FR2638357B1/fr not_active Expired - Fee Related
- 1989-10-30 DE DE3936112A patent/DE3936112C2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2001673C (en) | 1996-08-27 |
| GB8924286D0 (en) | 1989-12-13 |
| JPH02172918A (ja) | 1990-07-04 |
| FR2638357A1 (fr) | 1990-05-04 |
| FR2638357B1 (fr) | 1993-10-22 |
| IT8922164A1 (it) | 1991-04-27 |
| AT399277B (de) | 1995-04-25 |
| IT1239542B (it) | 1993-11-05 |
| GB2224207B (en) | 1992-06-10 |
| HUT51143A (en) | 1990-04-28 |
| CA2001673A1 (en) | 1990-04-28 |
| IL92138A0 (en) | 1990-07-12 |
| ATA247489A (de) | 1994-09-15 |
| DE3936112A1 (de) | 1990-05-31 |
| HU200926B (en) | 1990-09-28 |
| IT8922164A0 (it) | 1989-10-27 |
| GB2224207A (en) | 1990-05-02 |
| DE3936112C2 (de) | 1999-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2001673C (en) | Pharmaceutical composition containing piroxicam | |
| RU2181590C2 (ru) | Фармацевтические композиции, содержащие ирбесартан | |
| KR940002659B1 (ko) | 치료제 조성물의 제조방법 | |
| AU684522B2 (en) | Pharmaceutical thermal infusion process | |
| US9017722B2 (en) | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone | |
| CA1306686C (en) | Pharmaceutical composition containing ibuprofen | |
| US5824344A (en) | Pharmaceutical thermal infusion granules | |
| PL200957B1 (pl) | Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej | |
| US6656929B1 (en) | Pharmaceutical composition with a synthetic natural progesterone and oestradiol base and its preparation process | |
| TWI415633B (zh) | Solid preparations containing enteric solid dispersions | |
| IL96995A (en) | Pharmaceutical compositions containing pimobendan and their preparation | |
| CZ300558B6 (cs) | Tabletová kompozice nesteroidního protizánetlivého léciva a zpusob její prípravy | |
| JPH02164824A (ja) | 分散性製剤 | |
| MXPA04011634A (es) | Regimenes de tratamiento con bazedoxifeno. | |
| US6365196B1 (en) | Controlled release solid dosage forms of lithium carbonate | |
| US5827537A (en) | Pharmaceutical thermal infusion process | |
| JP2002068983A (ja) | ８−クロロ−６，１１−ジヒドロ−１１−（４−ピペリジリデン）−５Ｈ−ベンゾ［５，６］シクロヘプタ［１，２−ｂ］ピリジンの経口用組成物 | |
| CZ287149B6 (en) | Pharmaceutical preparation containing gemfibrozil | |
| NO318575B1 (no) | Stabile sammensetninger som omfatter levosimendan og alginsyre | |
| JP4429262B2 (ja) | フェノフィブラートの固体分散体 | |
| US6056974A (en) | Rapid-release S1452 tablets | |
| DK165168B (da) | Fremgangsmaade til fremstilling af et basesalt af piroxicam aflejret paa en farmaceutisk acceptabel baerer | |
| JPH10226644A (ja) | 医薬組成物 | |
| CZ289856B6 (cs) | Farmaceutický prostředek na bázi inhibitoru 5alfa-reduktázy | |
| KR20180112139A (ko) | 바제독시펜 또는 그의 약제학적으로 허용가능한 염, 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는 복합제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void |